drugset / Trial / NCT06962904
CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults
Phase 1
Active not recruiting
50 enrolled
Centers for Disease Control and Prevention
Children's Hospital Medical Center, Cincinnati · collabEmory-Children's Center · collabMicron Biomedical, Inc · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This is a study of CDC-9 inactivated rotavirus vaccine (IRV) microneedle patch (MNP) for intradermal administration in healthy adults aged 18 to 45 years at two dose levels in a 3-dose series. The purpose is to determine if it is safe and if the recipient's immune system responds to the vaccine.
Timeline
- Start
- 2025-07-07
- Primary completion
- 2026-10-06
- Completion
- 2026-10-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CDC-9 Inactivated Rotavirus Vaccine (IRV) | Vaccine | 3.75 ug | Intravenous |
| Subject | CDC-9 Inactivated Rotavirus Vaccine (IRV) | Vaccine | 7.5 ug | Intravenous |